Wells Fargo & Company MN lowered its stake in Spark Therapeutics Inc (NASDAQ:ONCE) by 46.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 253,563 shares of the biotechnology company’s stock after selling 223,187 shares during the quarter. Wells Fargo & Company MN owned about 0.69% of Spark Therapeutics worth $13,038,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Public Employees Retirement Association of Colorado acquired a new position in Spark Therapeutics in the fourth quarter valued at about $163,000. Aperio Group LLC increased its stake in Spark Therapeutics by 29.2% during the fourth quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 898 shares during the period. Teacher Retirement System of Texas purchased a new stake in Spark Therapeutics during the third quarter worth about $225,000. Prudential Financial Inc. purchased a new stake in Spark Therapeutics during the third quarter worth about $239,000. Finally, Commonwealth Equity Services Inc purchased a new stake in Spark Therapeutics during the third quarter worth about $257,000.
Shares of Spark Therapeutics Inc (NASDAQ:ONCE) opened at $67.51 on Friday. Spark Therapeutics Inc has a one year low of $41.06 and a one year high of $91.75.
A number of brokerages have issued reports on ONCE. BMO Capital Markets set a $64.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Spark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, March 1st. Credit Suisse Group reiterated an “outperform” rating and set a $75.00 price target (up from $61.00) on shares of Spark Therapeutics in a research note on Thursday, March 8th. Raymond James Financial set a $66.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Finally, Mizuho reiterated a “buy” rating and set a $79.00 price target on shares of Spark Therapeutics in a research note on Wednesday, February 21st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $70.58.
ILLEGAL ACTIVITY WARNING: “Spark Therapeutics Inc (ONCE) Holdings Reduced by Wells Fargo & Company MN” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://weekherald.com/2018/03/17/spark-therapeutics-inc-once-holdings-reduced-by-wells-fargo-company-mn.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.